David A. Siegel I Teos Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 18,200 shares of ITOS stock, worth $210,938. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,200Holding current value
$210,938% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding ITOS
# of Institutions
149Shares Held
36.3MCall Options Held
653KPut Options Held
1.48M-
Black Rock Inc. New York, NY3.73MShares$43.2 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.52MShares$40.8 Million0.79% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.25MShares$37.7 Million1.7% of portfolio
-
Boxer Capital, LLC San Diego, CA2.95MShares$34.2 Million2.43% of portfolio
-
Mpm Asset Management LLC Cambridge, MA2.74MShares$31.7 Million22.32% of portfolio
About iTeos Therapeutics, Inc.
- Ticker ITOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,575,300
- Market Cap $412M
- Description
- Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...